Saracatinib for epileptic seizures
The fyn kinase inhibitor, AZD0503 has demonstrated excellent clinical tolerability and oral bioavailability in humans.
This drug has gone through phase II clinical trial for a various types of cancers. ISU researchers have tested this drug in the mouse kainate model of temporal lobe epilepsy and found that it significantly reduced seizure onset at 25 mg/kg by oral route. They also observed a similar effect in fyn gene knockout mice.